U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Slides:



Advertisements
Similar presentations
Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
Advertisements

Effectiveness Evaluation for Production Drugs Crystal Groesbeck, Ph.D Division of Production Drugs.
Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.
Julianne Gee, MPH Immunization Safety Office
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Regulatory Toxicology James Swenberg, D.V.M., Ph.D.
Dr. ABDULLAH ABDU ALMIKHLAFY Assistant professor & Head of community medicine department Presented By University of Science & Technology Sana’a – Yemen.
Pork Checkoff National Pork Board.  Food Safety  Animal Well-Being.
Introduction to Regulation
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.
What Do Toxicologists Do?
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
Canine NSAIDs—What Dog Owners Should Know
Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.
Community Planning Training 1-1. Community Plan Implementation Training 1- Community Planning Training 1-3.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Good Laboratory Practices (GLPs)
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
Clinical causality assessment I. Ralph Edwards R.H.B Meyboom.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
INTRODUCTION TO RA.
MCA Risk:benefit analysis of Kava-kava Update as at 12 Feb 2002.
Investigational New Drug Application (IND)
When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Approved: 9 Jun DoD Leader’s Briefing: Force Health Protection Against Anthrax.
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.
DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
The NCI Central IRB Initiative Third Annual Medical Research Summit Washington, D.C. March 2003.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
Overview of Gene Therapy Surveillance Inspections Joseph P Salewski, Chief Bioresearch Monitoring Branch CBER.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
CAUSALITY ASSESSMENT OF SUSPECTED AEs Dr. Retesh Kumar Head, Global PhV Department 12/13/2015.
FDA Regulatory and Compliance Symposium
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.
PHARMACOVIGILANCE PLAN FOR TANZANIA PREPARED BY EMMA & MARY 10 TH SEPTEMBER 2004.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
JMAFF (Chair of Biologicals Quality Monitoring EWG)
Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.
Viagra (sildenafil citrate): Extensive Clinical and Post-Marketing Experience Michael Sweeney, MD Senior Medical Director Pfizer Inc.
CLINICAL TRIALS.
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Detection & monitoring of ADR
8. Causality assessment:
Introduction to Clinical Pharmacy
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Bozeman Health Clinical Research
9. Introduction to signal detection
Waiving Target Animal Batch Safety Testing for vaccines
Suzanne M. Sensabaugh, MS, MBA
The Role of the Private Vet
Ramy Abdelrahman, MD Division of Pediatric and Maternal Health (DPMH)
Regulatory Perspective of the Use of EHRs in RCTs
Presentation transcript:

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated.

FDAH Adverse Event Report Re-analysis David R. Hustead, D.V.M. Sr. Director, International Technical and Biological Regulatory Affairs Fort Dodge Animal Health January 31, 2005

FDAH Adverse Event Collection Professional Services Department Technical Support Adverse Event Investigations Regulatory Compliance Customer Support 28 DVMs with extensive clinical practice prior to joining industry 3 PhDs, 7 Vet Techs, 9 Support Staff

All reports of suspected adverse events are investigated To improve the quality of data collected, FDAH routinely pays for diagnostic services including specialist referrals All reports received, regardless of causality, are recorded and submitted to CVM FDAH Adverse Event Collection

Report Categories Injection Site Report Allergy Report Signs  48 hours & consistent with allergy for species Non-Allergy Report Lack of Efficacy Report FDAH Adverse Event Collection

Medical Association Assessment Based on VICH approved draft guidelines Each animal event assessed as a whole Three categories Medical Association Possible Product is at least one of equally plausible explanations for the event All events are initially assigned to possible category

Medical Association Assessment Medical Association Unlikely Sufficient information exists to establish event is not likely to have been associated with product, or there are other more plausible explanations Medical Association Probable All the following must be met, Reasonable association in time Adverse event is reasonable given the known pharmacology and toxicology of the drug No other equally plausible explanation

Comparison to Other Products Is Difficult Monthly oral products Administered at home by owner as “treats” Rates of use are dissimilar and difficult to know Different companies have a variety of systems to collect, investigate, quantify, and submit adverse observations as adverse event reports

For ProHeart 6, biases that may have stimulated reports of adverse observations are: ProHeart 6 is an innovative sustained-release product ProHeart 6 is administered parenterally by veterinarians Two “Dear Doctor” letters discussing ProHeart 6 safety issues Widely-disseminated news reports and website postings critical of ProHeart 6 Over-Reporting Bias

Practitioner presented with diagnostic dilemma Oral Preventive History rarely includes heartworm preventive administration regardless of diagnostic outcome Veterinarian does not make connection that preventive was given within last month ProHeart 6 Veterinarian knows when ProHeart 6 was given Likely to make temporal link to ProHeart 6 Leads to company contact for assistance Report submitted to CVM

Total AERs By Year 2003 Active Market Share Ivermectin + pyrantel % ProHeart % Milbemycin % CVM Annual AER Summary Number of reports for monthly preventives is lower in 2001 and 2002 In 2003, reporting of AERs for ProHeart 6 is comparable to that of the leading heartworm preventives

AERs by Year Excluding Inefficacy 2003 Active Market Share Ivermectin + pyrantel % ProHeart % Milbemycin % CVM Annual AER Summary When inefficacy reports are excluded, the reporting rate for ProHeart 6 remains comparable to that of leading heartworm preventives

Number of AERs by Quarter AVG/QTR thru Q2-04 = 421

Reporting Rate Total numbers of AERs, while valuable, fail to estimate incidence of the event and fail to account for change in use of product Reporting rates are calculated by dividing the number of AERs by the number of doses sold in the same period Reporting rate provides a better estimate of incidence

Reporting Rate By Quarter June 01 – May per 10,000 June 02 – May per 10,000 June 03 – May per 10,000

Reports Involving Death FDA previously presented that there are 485 deaths that are at least possibly related to ProHeart 6 FDAH was able to review the FDA’s causality assessments in 353 of these reports

CVM Causality Assessment Scores for Deaths Period covered: June 2001 through May 2004 Remotely 18% Possible 77%Probable 5%

Reports Involving Death FDA assesses 5% as “probably related” to ProHeart 6 (FDA score 3-4) FDA assesses 77% as “possibly related” to ProHeart 6 (FDA score 0-2) Should “possibly related” assessments support market recall?

Reports Involving Death Scientifically implausible events should be disregarded in conducting a meaningful review Remove events with concurrent vaccination Remove events with tumors (< 6 weeks) Remove events with FDA causality of zero 38% of events Remove events with incorrect causality assessment

FDA Causality Assessments FDAH carefully reviewed a subset of the available FDA assessment reports In 1/3 of these reports, the FDA assessed events as “possibly related” while FDAH assessed these events as “remotely related” 2 examples Dog with hemorrhagic episode; found to have significant levels of rodenticide in liver; FDA assessed as “possibly related” Dog presented with pain in abdomen 4 months post-ProHeart 6; dog was euthanized and necropsied – hemangiosarcoma of liver diagnosed; FDA assessed as “probably related”

ProHeart 6 Death Reports in Context ProHeart 6 mortality rate 500 per 12 million dogs per 2.5 years 20 per 1 million dogs per year General canine population mortality rate 5% per year 50,000 per 1 million dogs per year Given limitations of passive AE reporting systems, the level of death reported with ProHeart 6 is less than the expected mortality rate in dogs

FDAH AER Categories Allergy Reports (n = 2652) Signs include anaphylaxis, urticaria, itching Most occur within 48 hours of administration Systemic (non-allergy) Reports (n = 2510) Could involve any body system Signs not typical of “allergy” Time period not designated AERs in this category may have allergic etiology

Allergy AERs Reporting rate is low 1.26 per 10,000 doses sold > 80% allergic events are self-limiting and dog returns to normal Relative frequency decreases over time No breed predilection observed Reporting rate similar to FDAH vaccines and other common veterinary products

FDA has raised concerns about multiple body systems Anaphylaxis Convulsions Liver SGPT/ALT Liver lesions Low Platelets IMHA It is widely recognized that When products cause toxicity it is expected that a single/small number of target organs is affected In contrast, the wide variety of suspected adverse syndromes assigned to ProHeart 6 is inconsistent with established toxicological principles. Systemic AER

Non-Allergy AERs Expert review by body system Neurologic: Alexander deLahunta, DVM, PhD, DACVIM, Neurology Hematologic: Alan Rebar, DVM, PhD, DACVP, Clinical Pathology Hepatic: Alan Rebar, DVM, PhD, DACVP, Clinical Pathology Neoplasia: Philip Bergman, DVM, PhD, DACVIM, Oncology

Independent experts and FDAH conclude majority of AERs are: Not causally related to ProHeart 6 and reflect the normal range of diseases occurring in the dog population Conclusions AER Analysis

Summary and Conclusions Moxidectin based products for use in veterinary medicine are registered in over 70 countries. Extensive toxicology studies were conducted in mice, rats, and dogs to support the approval of moxidectin for use in food- producing animals In a 1-year dog toxicology study, the daily dosage of moxidectin resulting in a monthly moxidectin exposure that is 454-fold greater than dogs administered the recommended dose of ProHeart 6 resulted in no toxicologically significant findings

Summary and Conclusions The rate of submission of initial ADE reports to CVM decreased in 2003 and 2004, compared with 2002 ProHeart 6 is subject to substantial over-reporting bias Even with over-reporting bias and when corrected for market share the number of AERs associated with ProHeart 6 is similar to major competitors ProHeart SR 12 comparison to ProHeart 6 demonstrates similar reporting rates of AERs with an apparently lower reported rate of death

Summary and Conclusions While CVM identified 485 reports of death associated with ProHeart 6, FDAH estimates that only 5% of these reports were scored by CVM as “probably related” to ProHeart 6 The vast majority of allergic events are self-limiting, and the rate of allergic reports is low and decreasing The vast majority of the non-allergic events are not causally related to ProHeart 6, and likely reflect the normal range of disease occurring in canine population

Summary and Conclusions Dr. Glickman and colleagues recently conducted a unique study that evaluated over 7 million dog encounters at veterinary hospitals from 42 states. This landmark study in veterinary epidemiology demonstrated that: Concurrent use of vaccines demonstrates significant impact on AE rates the safety profile of ProHeart 6 is similar to 2 monthly heartworm preventives

Summary and Conclusions FDAH concludes that ProHeart 6 is a safe and effective product for prevention of heartworm disease